PMID- 22641678
OWN - NLM
STAT- MEDLINE
DCOM- 20120807
LR  - 20120529
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 32
IP  - 6
DP  - 2012 Jun
TI  - Functional design of chimeric T-cell antigen receptors for adoptive immunotherapy 
      of cancer: architecture and outcomes.
PG  - 2377-83
AB  - Adoptive immunotherapy using genetically modified T-cells with a chimeric antigen 
      receptor (CAR) is a promising modality for cancer treatment, because the 
      CAR-grafted T-cells can directly recognize and kill tumor cells, expressing a 
      specific tumor-associated antigen (TAA), in a human leukocyte antigen 
      (HLA)-independent manner. Optimal molecular designs of the CAR and a careful 
      choice of the target TAA are requisite to attain a significant response in 
      CAR-mediated therapy. This review provides a brief overview of the past studies 
      and the present state of CAR research, especially focusing on the development of 
      the CAR protein architecture.
FAU - Shirasu, Naoto
AU  - Shirasu N
AD  - Department of Biochemistry, Faculty of Medicine, Fukuoka University, 7-45-1 
      Jonan-ku, Fukuoka 814-0180, Japan. shirasu@fukuoka-u.ac.jp
FAU - Kuroki, Masahide
AU  - Kuroki M
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Receptors, Antigen, T-Cell)
RN  - 0 (Recombinant Fusion Proteins)
SB  - IM
MH  - Animals
MH  - Antigens, Neoplasm/*immunology
MH  - Antineoplastic Agents/chemical synthesis/chemistry/therapeutic use
MH  - Humans
MH  - Immunotherapy, Adoptive/*methods
MH  - Neoplasms/*therapy
MH  - Receptors, Antigen, T-Cell/chemistry/immunology/*therapeutic use
MH  - Recombinant Fusion Proteins/chemistry/immunology/therapeutic use
MH  - T-Lymphocytes/*transplantation
EDAT- 2012/05/30 06:00
MHDA- 2012/08/08 06:00
CRDT- 2012/05/30 06:00
PHST- 2012/05/30 06:00 [entrez]
PHST- 2012/05/30 06:00 [pubmed]
PHST- 2012/08/08 06:00 [medline]
AID - 32/6/2377 [pii]
PST - ppublish
SO  - Anticancer Res. 2012 Jun;32(6):2377-83.